Getting a product approved by the European Medicines Agency (EMA) can be daunting, especially for companies that have little experience with this unique and complex process. Within EMA, the Committee for Medicinal Products for Human Use (CHMP) conducts a scientific data review and recommends whether or not the drug or biologic should receive marketing authorization. CHMP holds meetings to get input and scientific advice to inform its decision and/or to discuss objections that might prevent or delay approval. For applicants, the goal is clear: get a positive majority vote for marketing authorization. However, multiple hurdles exist that can make preparing for these meetings quite challenging.
This presentation will walk you through how to prepare for, and manage, CHMP meetings to achieve a positive recommendation for your product. Upon the presentation’s conclusion attendees will:
This program is brought to you by the RAPS Chicago Chapter and is intended to promote knowledge sharing and engagement with others in the local regulatory community. Dinner will be provided and RAC holders may claim two RAC recertification credits.
Regulatory Affairs Professionals Society (RAPS)5635 Fishers Lane, Suite 400Rockville, Maryland 20852
raps@raps.org+1 301 770 2920
JoinMy RAPS DashboardLearn More
About UsTerms of UsePrivacy Policy